SCHEMBL924425

SCHEMBL924425

NC(=O)c1ccc(O)c(O)c1O

nearest known ligand 0.62

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SELL P14151 1/20 0.62
SELP P16109 1/20 0.62
HDAC1 Q13547 1/20 0.52
KDM4E B2RXH2 3/20 0.50
ALDH1A1 P00352 2/20 0.50
MAPT P10636 2/20 0.50
HPGD P15428 2/20 0.50
HSD17B10 Q99714 2/20 0.50
TSHR P16473 1/20 0.50
ERN1 O75460 1/20 0.47
PIK3CA P42336 4/20 0.46
TERT O14746 1/20 0.43
CHUK O15111 1/20 0.41
ALOX15 P16050 1/20 0.41
RECQL P46063 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30211643 0.89 ERN1 (0.54) SELLSELPHDAC1KDM4EALDH1A1
SCHEMBL3424158 0.89 ERN1 (0.54) SELLSELPHDAC1KDM4EALDH1A1
SCHEMBL424097 0.83 KDM4E (0.67) SELLSELPKDM4EALDH1A1MAPT
SCHEMBL29552052 0.83 KDM4E (0.67) SELLSELPKDM4EALDH1A1MAPT
SCHEMBL8548472 0.81 KDM4E (0.46) SELLSELPHDAC1KDM4EALDH1A1
SCHEMBL10550107 0.81 KDM4E (0.46) SELLSELPHDAC1KDM4EALDH1A1
SCHEMBL30366773 0.81 KDM4E (0.46) SELLSELPHDAC1KDM4EALDH1A1
Hydrochloric Acid SCHEMBL9377889 0.81 KDM4E (0.64) SELLSELPKDM4EALDH1A1MAPT
Ammonia Solution, Strong SCHEMBL8664317 0.81 KDM4E (0.64) SELLSELPKDM4EALDH1A1MAPT
SCHEMBL11054445 0.80 SELL (0.62) SELLSELPKDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230022235-A1 DUAL ANDROGEN RECEPTOR/AKR1C3 INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-01-26 US claimed
EP-4061351-A1 DUAL ANDROGEN RECEPTOR/AKR1C3 INHIBITORS The Regents of the University of California (US) 2022-09-28 EP claimed
CN-114727975-A Antiandrogen receptor/AKR 1C3 inhibitors 加利福尼亚大学董事会 2022-07-08 CN claimed
WO-2021101903-A1 DUAL ANDROGEN RECEPTOR/AKR1C3 INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-05-27 WO claimed
EP-0610444-B1 Use of a polyhydroxybenzamide or a derivative thereof in the manufacture of a medicament for treating viral infectious diseases ELFORD HOWARD L (US) 2003-01-29 EP claimed
EP-0900781-B1 Phenolic acid amides of hydroxy substituted benzylamines HAARMANN & REIMER GMBH (DE) 2002-03-20 EP claimed
EP-4711432-A1 ADHESIVE TAPE, CHEMICAL SOLUTION TANK, AND METHOD FOR PRODUCING CHEMICAL SOLUTION TANK Sekisui Chemical Co., Ltd. (JP) 2026-03-18 EP disclosed
US-12564630-B2 Vaccine adjuvants VIROVAX LLC (US) 2026-03-03 US disclosed
WO-2025079595-A1 ADHESIVE SHEET, LAMINATED SHEET, CHEMICAL LIQUID TANK, AND METHOD FOR MANUFACTURING CHEMICAL LIQUID TANK 積水化学工業株式会社 2025-04-17 WO disclosed
CN-119799806-A Preparation process for efficiently producing gallic acid 广州卫生职业技术学院 2025-04-11 CN disclosed
WO-2024232419-A1 ADHESIVE SHEET, MULTILAYER SHEET, CHEMICAL LIQUID TANK, AND METHOD FOR PRODUCING CHEMICAL LIQUID TANK 積水化学工業株式会社 2024-11-14 WO disclosed
WO-2024232418-A1 ADHESIVE TAPE 積水化学工業株式会社 2024-11-14 WO disclosed
WO-2024232420-A1 ADHESIVE TAPE, CHEMICAL SOLUTION TANK, AND METHOD FOR PRODUCING CHEMICAL SOLUTION TANK 積水化学工業株式会社 2024-11-14 WO disclosed
US-4623659-A RIBONUCLEOTIDE REDUCTASE INHIBITORS RIET BARTHOLOMEUS VAN T (US) 1986-11-18 US disclosed
EP-0144396-A4 POLYHYDROXYBENZOIC ACID DERIVATIVES. RIET BARTHOLOMEUS VAN T (US) 1986-08-21 EP disclosed
EP-0144396-A1 POLYHYDROXYBENZOIC ACID DERIVATIVES. RIET BARTHOLOMEUS VAN T (US) 1985-06-19 EP disclosed
WO-1984004676-A1 POLYHYDROXYBENZOIC ACID DERIVATIVES RIET BARTHOLOMEUS VAN T 1984-12-06 WO disclosed
US-4448730-A ANTITUMOR AGENTS RIET BARTHOLOMEUS VAN T 1984-05-15 US disclosed
US-4394389-A ANTITUMOR AGENTS RIET BARTHOLOMEUS VAN T 1983-07-19 US disclosed
US-4263322-A RIBONUCLEOTIDE REDUCTASE INHIBITORS RIET BARTHOLOMEUS VAN T 1981-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230022235-A1 DUAL ANDROGEN RECEPTOR/AKR1C3 INHIBITORS AKR1C3, AR, AKR1C4 SELL 4852/4885SELP 4778/4885HDAC1 203/4885
US-12564630-B2 Vaccine adjuvants TLR7, TLR8, TLR3 SELL 3032/4885SELP 2608/4885HDAC1 3192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.